Details for Patent: 9,012,437
✉ Email this page to a colleague
Title: | Implants and methods for treating inflammation-mediated conditions of the eye |
Abstract: | Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks. |
Inventor(s): | Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos, CA) |
Assignee: | Allergan, Inc. (Irvine, CA) |
Filing Date: | May 03, 2013 |
Application Number: | 13/886,465 |
Claims: | 1. A method for treating an inflammation-mediated condition of the eye comprising: implanting into the vitreous of the eye a bioerodible implant consisting of dexamethasone and a bioerodible polymer, wherein the implant delivers the dexamethasone to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/mL dexamethasone within about 48 hours, and maintains a concentration equivalent to at least about 0.03 .mu.g/mL dexamethasone for at least about three weeks, wherein the implant is produced by an extrusion method, wherein the total weight of the implant is about 500-1000 .mu.g, and wherein the inflammation-mediated condition of the eye is selected from the group consisting of macular edema, acute macular degeneration, retinal detachment, or proliferative vitreoretinopathy (PVR). 2. The method of claim 1, wherein the bioerodible polymer is a polylactic acid polyglycolic acid (PLGA) copolymer. 3. The method of claim 2, wherein the PLGA copolymer is a 50/50 PLGA copolymer. 4. The method of claim 3, wherein the dexamethasone is from about 10 to 90% by weight of the implant. 5. The method of claim 4, wherein the dexamethasone is from about 50 to about 80% by weight of the implant. |